Abstract
The postnatal forebrain subventricular zone (SVZ) harbors stem cells that give rise to olfactory bulb interneurons throughout life. The identity of stem cells in the adult SVZ has been extensively debated. Although, ependymal cells were once suggested to have stem cell characteristics, subsequent studies have challenged the initial report and postulated that subependymal GFAP+ cells were the stem cells. Here, we report that, in the adult mouse forebrain, immunoreactivity for a neural stem cell marker, prominin-1/CD133, is exclusively localized to the ependyma, although not all ependymal cells are CD133+. Using transplantation and genetic lineage tracing approaches, we demonstrate that CD133+ ependymal cells continuously produce new neurons destined to olfactory bulb. Collectively, our data indicate that, compared with GFAP expressing adult neural stem cells, CD133+ ependymal cells represent an additional—perhaps more quiescent—stem cell population in the mammalian forebrain.
Keywords: adult neural stem cells, subventricular zone
The adult mammalian brain harbors new neurons throughout life in two discrete locations: hippocampus and subventricular zone (SVZ) [also referred to as subependymal zone (SEZ)] (1–4). Immature neurons generated in the SVZ travel along the rostral migratory stream (RMS) and become postmitotic interneurons in the olfactory bulb. The identity of the stem cells in the adult SVZ has been debated extensively. Glial fibrillary acidic protein (GFAP) expressing cells have been suggested to be the stem cells that give rise to a Dlx2+ transiently fast amplifying neural progenitor population, which eventually generates PSA-NCAM+ neuroblasts (5). However, the placement of LeX+ or Nestin+ adult SVZ stem/progenitor cells into the current lineage model has not been carefully determined. Ependymal cells, which form a multiciliated single cell layer lining the ventricles and are in close proximity to the cells of the SVZ, were also suggested to have stem cell characteristics (6); however, subsequent studies have challenged the initial report (5, 7, 8). To date, the contribution of ependymal cells to the lineage of the postnatal SVZ still remains controversial.
Increasing evidence suggests that a number of “common” genes are shared by the stem cells of different tissue types. One of these markers, CD133 (prominin-1), has been detected in a number of stem cells, including myogenic and hematopoietic stem cells (9). CD133 expression was shown in embryonic stem cell derived neural stem cells in culture (10), putative neural stem cells of the cerebellum (11), and embryonic neuroepithelial cells (12, 13). In addition to the native stem cells, CD133 is present on numerous types of cancer stem cells, including retinoblastoma, leukemias, and brain tumors (14, 15). Collectively, CD133-immunoreactivity provides an important tool to recognize various stem cell populations.
In this study, we identified CD133 expressing cells exclusively in the postnatal ependyma. A subpopulation of ependymal cells that are CD133+ possess classical neural stem cell characteristics in vitro and give rise to stem/progenitor cells expressing Nestin, LeX or GFAP. Furthermore, quiescent CD133+ ependymal cells in vivo retain the capacity for cell division and become activated upon injury. Using transplantation and genetic lineage tracing, we demonstrate that CD133+ ependymal cells generate new neurons that become part of the postnatal SVZ. Collectively, our data indicate that CD133 expressing ependymal cells render a quiescent stem cell population in the mammalian forebrain.
Results
Primary Location of the Cells Expressing CD133 in the Postnatal Forebrain.
In embryonic day (E)9, E12, and E15 telencephalon, CD133 expression was restricted to the ventricular zone (VZ) [supporting information (SI) Fig. 6 a-c]. Postnatally [i.e., postnatal day (P)0 through adulthood], CD133-immunoreactivity was localized to a “subpopulation” of the one-cell-thick layer lining the walls of the lateral ventricles, the ependyma (Fig. 1 a–e). In all cases, postnatal CD133+ cells were adjacent to the overlying SEZ and displayed a multiciliated morphology extending into the lateral ventricles—different from the single/short process bearing GFAP+ cells (Fig. 1 a–e and k). Using in situ hybridization, we demonstrated exclusive expression of prominin-1 mRNA in the forebrain by the ependymal cells (Fig. 1f). Furthermore, CD133+ cells were colabeled with S100β (Fig. 1i), a known—but not exclusive—marker of the ependymal cells (8). Although all of the ependymal cells were immunoreactive for β-IV tubulin—a marker that labels cilia (16)—only a subpopulation of ependymal cells was CD133+/β-IV tubulin+ (Fig. 1g). Moreover, some CD133+ ependymal cells were also immunoreactive for CD24 (SI Table 1), a surface protein that is present on some of the ependymal cells, and on the neuroblasts in the SEZ (Fig. 1h). CD133+ ependymal cells did not colocalize either with PSA-NCAM+ neuroblasts (Fig. 1j) or GFAP expressing cells (Fig. 1k) of the adult SEZ. Our findings reveal that cells expressing the stem cell marker CD133 persist throughout development and proceed into adulthood as part of the ependyma.
Stem Cell Characteristics of the Adult CD133+ Ependymal Cells in Vitro.
To determine whether CD133+ cells possess characteristics of neural stem cells, we microdissected and dissociated the walls of the lateral ventricles into single cells from early postnatal and adult mice. CD133+ cells were purified by using fluorescence-activated cell sorting (FACS). Using quantitative-RT-PCR, we demonstrated enrichment of CD133 signal in the sorted cell populations (SI Fig. 7a).
Sorted CD133+ cells gave rise to all three lineages of the CNS, when grown and differentiated on adherent surfaces for 6–9 days (SI Fig. 7 b–d). When plated on uncoated surfaces at a clonal density in the presence of fibroblast growth factor (bFGF), sorted CD133+ cells formed neurospheres at a 5.9% rate (Fig. 2 a and d). During the early stages of sphere development, most of the CD133+ neurospheres were motile and displayed a “spinning” type of motion, a behavior associated with ependymal spheres (7, 8). Once primary spheres were dissociated and plated clonally as single cells, secondary (6.6%), tertiary (6.1%), quaternary (6.9%), and quinary (7.2%) spheres formed, indicating that CD133+ cells self-renew for prolonged time points in vitro (17) (Fig. 2 b and d). With each passage, CD133+ cell population in neurospheres remained constant (i.e., 12.9, 13.2, and 12.1% in primary, secondary, and tertiary neurospheres, respectively) as shown by FACS analysis (Fig. 2e). Using RT-PCR, we detected CD133 and LeX expression from primary neurospheres at 6 days in vitro (DIV) under bFGF treatment (Fig. 2f). Note that GFAP was not expressed by the cells in the neurospheres under proliferation conditions and was up-regulated upon differentiation of primary neurospheres (Fig. 2f). When CD133+ cell-initiated neurospheres (Fig. 2g) were plated on PO-Fn coated slides in the absence of bFGF, they differentiated and gave rise to neurons, astrocytes, and oligodendrocytes, demonstrating the multipotency of CD133+ stem cells (Fig. 2 h–j).
In previous reports, ependymal cells were postulated to lack stem cell properties, when CD24-immunoreactivity was used to identify ependymal cells (5, 7). However, CD24 is expressed also in the PSA-NCAM+ neuroblasts in the SEZ (18), making CD24 a nonspecific marker for ependymal cells. Nevertheless, to test whether CD24+ cells behave as stem cells in our culture conditions, we sorted and plated CD24+ cells in exactly the same way as CD133+ cells. A very small percentage of CD24+ cells (i.e., 0.9%) generated spheres that were smaller and did not yield any secondary spheres (Fig. 2 c and d), similar to the findings of previous studies (7, 8). Our data indicate that only CD133+/CD24− ependymal cells carry stem cell potential.
Induction of Quiescent CD133+ Stem Cells upon Chemical Insult/Injury.
Although ependymal cells have been suggested to divide infrequently in vivo (5, 7), our analysis of large scale adult brain sections demonstrated occasional proliferating CD133+ cells, using Ki67-immunoreactivity (Fig. 3 a and b). To test whether relatively quiescent ependymal cells can be activated in vivo, we injected the anti-mitotic agent Cytosine-β-d-arabinofuranoside (Ara-C) into the lateral ventricles of adult mice. Ara-C treatment selectively eliminates fast dividing cells (5) and presumably induces resident stem cells to proliferate in response. Injected animals were administered BrdU for 2 weeks. We detected CD133+/BrdU+ cells (Fig. 4 c–f), indicating that CD133 expressing ependymal cells remain “inducible” for cell division.
Generation of New Neurons by CD133+ Ependymal Stem Cells in the Adult SVZ/RMS in Vivo.
To determine the progeny of CD133+ ependymal cells, we used Nestin/GFP transgenic mice, in which the expression of GFP is under the control of nestin (19). In these animals, Nestin/GFP expressing cells mark the postnatal SVZ and RMS very distinctly (Fig. 4a). Furthermore, the half life of GFP protein is longer compared with Nestin, making it possible to partially trace cells that had expressed Nestin in their lineage history. When CD133+ cells were collected from Nestin/GFP mice, using FACS, virtually all of them were GFP− (Fig. 4b). In addition, CD133+ cells were not immunoreactive for LeX, GFAP, or Nestin (Fig. 4 c–e). However, increasing number of GFP+ green spheres that were clonally originated from CD133+ ependymal neural stem cells was observed 3–7 DIV. Nestin/GFP+ neurospheres also contained LeX+ stem cells (Fig. 4 f–k).
To characterize the progeny of CD133+ stem cells in the adult forebrain, we traced them in vivo, using a transplantation approach. Purified CD133+/GFP− cells from adult Nestin/GFP mice were injected into the lateral ventricles of wild type adult animals. At the time of injections, none of the sorted CD133+ cells were GFP+. We observed a number of GFP+ cells along the RMS 1 or 2 weeks after transplantation (Fig. 4l), indicating that CD133+ cells integrate into the recipient tissue and produce cells destined for SVZ/RMS in vivo. Furthermore, none of the GFP+ cells, even in the close proximity of the lateral ventricle, were colabeled with CD133 (Fig. 4m). GFP+ cells were immunoreactive for the immature neuronal marker doublecortin (Fig. 4n), the astrocytic—or adult stem cell—marker GFAP (Fig. 4o), or the proneural bHLH transcription factor Mash1 (Fig. 4p). Most of the GFP+ cells were colocalized with PSA-NCAM+ neuroblasts (Fig. 4q), although none of them costained with Olig2 (Fig. 4r).
We further examined the contribution of CD133+ ependymal stem cells to the lineage of postnatal SVZ, using a genetic approach. Human CD133 analog, AC133, contains four promoters in front of alternative start sites in exon 1 (SI Fig. 8). Exon 1B is the main splice variant used in the brain under the control of the P2 promoter (20) (SI Fig. 8). We excised the mouse CD133 promoter fragment that contains the sequence homologues to the human P2 promoter (designated “mP2”) and inserted it into an expression vector containing Cre-GFP fusion protein. Furthermore, in another vector, we replaced the prominin promoter—upstream of Cre-GFP—with a short 2.0-kb GFAP promoter to label postnatal GFAP+ cells (5).
The specificity of mP2 and GFAP promoters were characterized in vitro and in vivo. Dissociated cells from the lateral ventricles were transfected with mP2 and GFAP promoters 1 day after plating. Analysis of GFP-Cre+ cells 2 days after transfection demonstrated that mP2 minimal promoter construct was specific to CD133+cells, whereas the GFAP promoter was solely expressed by GFAP+ cells (SI Fig. 9). Subsequently, mP2 or GFAP expression plasmids were injected into the lateral ventricles of wild type P3 pups, followed by electroporation to transfect cells surrounding the ventricles. Four or 7 days after injection, GFP+ cells were exclusively detected in the ependymal layer and none in the SEZ (Fig. 5 a and b and SI Fig. 10 a and b). Moreover, every GFP+ mP2-transfected ependymal cell was CD133+ (Fig. 5b and SI Fig. 10a) and GFAP− (SI Fig. 10b), demonstrating the specificity of the mP2 construct in vivo. Unlike in the case of Nestin/GFP, where GFP is relatively long-lived, our experimental data suggest that Cre-GFP fusion protein is relatively short-lived, because we never observed any CD133− cells expressing GFP 7 days postinjection. In animals that were injected with the GFAP promoter, GFP+ cells were only detected in the subependyma, and none were detected in the ependyma (SI Fig. 10 c and d). Additionally, GFAP promoter transfected cells were GFAP-immunoreactive (SI Fig. 10c), but none of them were CD133+ (SI Fig. 10d). Collectively, these data indicated that electroporation of the CD133 minimal promoter allows for highly specific transgene expression in CD133+ ependymal cells.
To trace the progeny of CD133+ ependymal stem cells in vivo, we used a Rosa26-lacZ mouse reporter line that contains a “floxed” stop codon in front of a lacZ gene at the Rosa26 locus. mP2 plasmid was injected into the lateral ventricles of P3 and adult Rosa26 mice followed by electroporation. This approach allows for identification of the mP2 transfected cells, using Cre-GFP, and the progeny of the transfected cells, using β-gal. One week after the injection of mP2, we detected numerous β-gal+ cells that were PSA-NCAM+ with a typical morphology of migrating neurons in the SVZ and RMS (Fig. 5 c–e and g). Two weeks after injection, a number of β-gal+ cells that were immunoreactive for TuJ1 was located in the layers of the olfactory bulb (Fig. 5 f–k).
We examined mP2-transfected cells to determine the source of β-gal+ cells in the RMS of Rosa26 reporter animals. We exclusively detected GFP+ cells in the ependymal layer lining the ventricles (Fig. 5a) and none in the SEZ. Moreover, every GFP+ transfected ependymal cell was also CD133+ (Fig. 5b). Subsequently, the same injection protocol was repeated by using adult Rosa26 reporter mice. We again detected GFP+ cells in the ependymal layer—and none in the SEZ—(Fig. 5m) and β-gal+ cells along the RMS 2–4 weeks after injection (Fig. 5 l–n). In addition, every GFP+ transfected ependymal cell was also CD133+ (Fig. 5o), indicating that the proliferation capacity of CD133+ ependymal cells is not restricted to neonatal period. Note that electroporation by itself does not reactivate ependymal stem cells (data not shown). Collectively, our transplantation and genetic tracing experiments in neonatal and adult mice demonstrate the in vivo stem cell activity of CD133+ ependymal cells and their contribution to the lineage of postnatal SVZ.
Discussion
Work over the last decade revealed that neural stem cells persist in the adult mammalian forebrain and generate new neurons throughout life, but the nature of these stem cells is incompletely understood. CD133 is a broadly accepted marker for stem cells, including neural stem cells (15). However, the location and identity of CD133 expressing cells in the mammalian brain remain elusive. In this study, we reveal that a subpopulation of adult ependymal cells, expressing CD133, fulfills the criteria of bona fide neural stem cells in vivo and in vitro. Furthermore, we show that ependymal cells expressing CD24 (regardless of whether they also express CD133 or not) do not exhibit stem cell characteristics, which may explain why previous studies that used CD24 to identify ependymal stem cells had reached the conclusion that the ependyma does not contain neural stem cells.
More than One Neural Stem Cell Population in the Adult CNS.
We demonstrate that the cells expressing the stem cell marker CD133 belong to a subpopulation of postnatal ependymal cells. Although our data do not argue against the observation that GFAP+ and/or LeX+ subependymal cells also fulfill the current neural stem cell criteria, we propose that CD133+ ependymal cells represent a more quiescent neural stem cell population that is upstream of GFAP and/or LeX expressing cells. Furthermore, our data do not exclude the possibility of GFAP+ or LeX+ cells reciprocally giving rise to CD133+ ependymal stem cells. The presence of more than one type of stem cell in a particular system is well established. For example, the hematopoietic system contains both long-term and short-term stem cells (21), whereas, in the mammalian skin, two types of epithelial stem cells are present (22). Thus, it is plausible that the adult nervous system may also contain different types of stem cells.
Quiescent Adult Neural Stem Cells.
In agreement with reports that described the quiescence of ependymal cells (5, 7, 23), we also found that CD133+ ependymal cells are more quiescent compared with GFAP+ subependymal cells. However, our data indicate that the ependyma is not 100% postmitotic. Occasionally, CD133+ cells in a mitotic cycle (i.e., Ki67+) could indeed be detected in the ependyma. Additionally, in response to anti-mitotic drugs, increased activation of mitotic features in the CD133+ependymal cells can be observed. It has been reported that ependymal cells originate from embryonic radial glial cells that are generally considered as the multipotent neural stem cells in embryonic stages (23). Although the same report postulated that ependymal cells were absolutely postmitotic, the negative data do not preclude the possibility that some quiescent neural stem cells (e.g., radial glial cells) in the developing embryos may preserve their quiescence into adult stages when they become ependymal cells.
Our in vitro stem cell assays and in vivo transplantation experiments indicate that CD133+ ependymal cells satisfy all of the criteria of a bona fide neural stem cell. More importantly, our genetic-lineage tracing experiments and BrdU and Ki67 labeling results clearly demonstrate that the adult ependyma is not 100% postmitotic and that ependymal cells give rise to olfactory bulb interneurons on a regular basis. It is possible that differences in mouse strains and age and analytic approaches can increase or decrease the detectability of mitotic figures in the ependyma.
The “Neurogenic Niche” and the “Neural Stem Cell Niche.”
Because CD133+ ependymal cells are constantly in contact with the cerebrospinal fluid (CSF), we propose that the CSF supports a potential neural stem cell niche for the adult SVZ, which leads neural stem cells to temporarily withdraw from the cell cycle and enter a quiescent state (see SI Fig. 11 and SI Text for details). In the adult, Notch signaling is active in the ependyma, which might be involved in maintaining neural stem cells in an undifferentiated quiescent state (6). Inhibition of this pathway might be involved in stem cell activation. Consistently, in the developing cerebral cortex, it has been shown that CD133+/Notchhigh cells display neural stem cell features, whereas Notchlow cells are actively involved in neurogenesis (24).
In recent years, rapid proliferation capability has been regarded as representative for “stemness” in neural stem cells. As a result, it is generally believed that the neural stem cell niche should contain activities that enhance proliferation and neurogenic potential of stem cells. We propose that such a niche should be more appropriately referred to as the neurogenic niche. In the field of neural stem cell research, the neurogenic niche has often been used interchangeably with the neural stem cell niche, which is rather misleading. We suggest that similar to stem cell niches in other systems, the neural stem cell niche should be involved in maintaining stem cells in a multipotent, and mitotically, and metabolically quiescent state, thus preserving the stem cells. It is worth noting that CD133+ ependymal cells are also located in the third and fourth ventricles and the central canal of the spinal cord (SI Fig. 6). Although these cells may still contain stem cell properties, because of the lack of a neurogenic niche, they do not produce new neurons on a regular basis. Because ≈6% of the CD133+ cells form neurospheres, we cannot exclude the possibility that not all CD133+ cells (e.g., CD133+/CD24+) are stem cells. The quiescent nature of CD133+ ependymal cells makes them more comparable with the stem cells found in other systems, such as skin stem cells (22) and Drosophila germ-line stem cells (25), than do the previously postulated adult neural stem cell populations (GFAP+ and/or LeX+ cells). Although CD133+ cells can give rise to fast-proliferating progeny, our finding that CD133+ neural stem cells are normally quiescent ependymal cells in vivo suggests that the nervous system, similar to other systems, harbors multipotent quiescent stem cells, and that the previously identified neural stem cells in adult brain may represent a more downstream cell population.
Materials and Methods
Surgery.
Neonatal and adult mice were transcardially perfused by using 4% PFA. All brains were processed as described in ref. 26. Using stereotaxic coordinates, dissociated cells or plasmid DNA constructs were injected into the lateral ventricles, followed by electroporation. Details of surgical procedures are provided in SI Text.
Cell Culture.
A modified protocol was used to culture postnatal SVZ cells (26). Dissociated cells were isolated by using FACS. For a detailed description, see SI Text.
Immunostaining, in Situ Hybridization, EM.
Analyses were performed as described in ref. 26. For a detailed description, see SI Text.
Promoter Constructs and Transfection.
Mouse prominin-1 promoter or the 2.0-kb GFAP promoter was subcloned into the pGL3B (Promega) containing Cre-GFP fusion. mP2 and GFAP constructs were used in conjunction with electroporation or in vitro.
Supplementary Material
ACKNOWLEDGMENTS.
We thank Drs. Harley Kornblum and Michael Sofroniew for their comments on the manuscript; Marianne Cilluffo and the University of California, Los Angeles Brain Research Institute Electron Microscopy Core Facility; and Dr. Denis Corbeil for prominin-1 plasmid. V.C. is a Jonsson Comprehensive Cancer Center fellow. This work was supported by a Klingenstein Neuroscience Award (to Y.E.S.), grants from the Alzheimer's Association (to Y.E.S.), and National Institute of Child Health and Development Program Project Grant HD006576 (to J.d.V. and Y.E.S.).
Footnotes
The authors declare no conflict of interest.
This article is a PNAS Direct Submission.
See Commentary on page 829.
This article contains supporting information online at www.pnas.org/cgi/content/full/0710000105/DC1.
References
- 1.Luskin MB. Neuron. 1993;11:173–189. doi: 10.1016/0896-6273(93)90281-u. [DOI] [PubMed] [Google Scholar]
- 2.Lois C, Alvarez-Buylla A. Science. 1994;264:1145–1148. doi: 10.1126/science.8178174. [DOI] [PubMed] [Google Scholar]
- 3.Gage FH. Science. 2000;287:1433–1438. doi: 10.1126/science.287.5457.1433. [DOI] [PubMed] [Google Scholar]
- 4.Coskun V, Luskin MB. J Neurosci. 2001;21:3092–3103. doi: 10.1523/JNEUROSCI.21-09-03092.2001. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Doetsch F, Caille I, Lim DA, Garcia-Verdugo JM, Alvarez-Buylla A. Cell. 1999;97:703–716. doi: 10.1016/s0092-8674(00)80783-7. [DOI] [PubMed] [Google Scholar]
- 6.Johansson CB, Momma S, Clarke DL, Risling M, Lendahl U, Frisen J. Cell. 1999;96:25–34. doi: 10.1016/s0092-8674(00)80956-3. [DOI] [PubMed] [Google Scholar]
- 7.Capela A, Temple S. Neuron. 2002;35:865–875. doi: 10.1016/s0896-6273(02)00835-8. [DOI] [PubMed] [Google Scholar]
- 8.Chiasson BJ, Tropepe V, Morshead CM, van der Kooy D. J Neurosci. 1999;19:4462–4471. doi: 10.1523/JNEUROSCI.19-11-04462.1999. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Miraglia S, Godfrey W, Yin AH, Atkins K, Warnke R, Holden JT, Bray RA, Waller EK, Buck DW. Blood. 1997;90:5013–5021. [PubMed] [Google Scholar]
- 10.Kania G, Corbeil D, Fuchs J, Tarasov KV, Blyszczuk P, Huttner WB, Boheler KR, Wobus AM. Stem Cells. 2005;23:791–804. doi: 10.1634/stemcells.2004-0232. [DOI] [PubMed] [Google Scholar]
- 11.Lee A, Kessler JD, Read TA, Kaiser C, Corbeil D, Huttner WB, Johnson JE, Wechsler-Reya RJ. Nat Neurosci. 2005;8:723–729. doi: 10.1038/nn1473. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Marzesco AM, Janich P, Wilsch-Brauninger M, Dubreuil V, Langenfeld K, Corbeil D, Huttner WB. J Cell Sci. 2005;118:2849–2858. doi: 10.1242/jcs.02439. [DOI] [PubMed] [Google Scholar]
- 13.Uchida N, Buck DW, He D, Reitsma MJ, Masek M, Phan TV, Tsukamoto AS, Gage FH, Weissman IL. Proc Natl Acad Sci USA. 2000;97:14720–14725. doi: 10.1073/pnas.97.26.14720. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Reya T, Morrison SJ, Clarke MF, Weissman IL. Nature. 2001;414:105–111. doi: 10.1038/35102167. [DOI] [PubMed] [Google Scholar]
- 15.Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano MD, Dirks PB. Nature. 2004;432:396–401. doi: 10.1038/nature03128. [DOI] [PubMed] [Google Scholar]
- 16.Renthal R, Schneider BG, Miller MM, Luduena RF. Cell Motil Cytoskeleton. 1993;25:19–29. doi: 10.1002/cm.970250104. [DOI] [PubMed] [Google Scholar]
- 17.Reynolds BA, Rietze RL. Nat Methods. 2005;2:333–336. doi: 10.1038/nmeth758. [DOI] [PubMed] [Google Scholar]
- 18.Calaora V, Chazal G, Nielsen PJ, Rougon G, Moreau H. Neuroscience. 1996;73:581–594. doi: 10.1016/0306-4522(96)00042-5. [DOI] [PubMed] [Google Scholar]
- 19.Yamaguchi M, Saito H, Suzuki M, Mori K. Neuroreport. 2000;11:1991–1996. doi: 10.1097/00001756-200006260-00037. [DOI] [PubMed] [Google Scholar]
- 20.Shmelkov SV, Jun L, St Clair R, McGarrigle D, Derderian CA, Usenko JK, Costa C, Zhang F, Guo X, Rafii S. Blood. 2004;103:2055–2061. doi: 10.1182/blood-2003-06-1881. [DOI] [PubMed] [Google Scholar]
- 21.Morrison SJ, Uchida N, Weissman IL. Annu Rev Cell Dev Biol. 1995;11:35–71. doi: 10.1146/annurev.cb.11.110195.000343. [DOI] [PubMed] [Google Scholar]
- 22.Blanpain C, Lowry WE, Geoghegan A, Polak L, Fuchs E. Cell. 2004;118:635–648. doi: 10.1016/j.cell.2004.08.012. [DOI] [PubMed] [Google Scholar]
- 23.Spassky N, Merkle FT, Flames N, Tramontin AD, Garcia-Verdugo JM, Alvarez-Buylla A. J Neurosci. 2005;25:10–18. doi: 10.1523/JNEUROSCI.1108-04.2005. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Mizutani K, Yoon K, Dang L, Tokunaga A, Gaiano N. Nature. 2007;449:351–355. doi: 10.1038/nature06090. [DOI] [PubMed] [Google Scholar]
- 25.Lin H. Nat Rev Genet. 2002;3:931–940. doi: 10.1038/nrg952. [DOI] [PubMed] [Google Scholar]
- 26.Ge W, He F, Kim KJ, Blanchi B, Coskun V, Nguyen L, Wu X, Zhao J, Heng JI, Martinowich K, et al. Proc Natl Acad Sci USA. 2006;103:1319–1324. doi: 10.1073/pnas.0510419103. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.